Skip to nav Skip to content

Clinical Trial Search

363 Clinical Trials Found

Clinical Trial 23226

Disease Site: Leukemia, other, Myeloid and Monocytic Leukemia
PI: Mishra, Asmita

Clinical Trial 23154

Disease Site: Other
PI: Sallman, David

Clinical Trial 20870

Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
Disease Site: Other Female Genital, Ovary
PI: Chern, Jing-Yi

Clinical Trial 23454

Disease Site: Soft Tissue
PI: Gaballa, Sameh

Clinical Trial 23581

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer
Disease Site: Lung
PI: Puri, Sonam

Clinical Trial 23641

Disease Site: Unknown Sites
PI: Pidala, Joseph

Clinical Trial 22617

Disease Site: Breast
PI: Soyano Muller, Aixa

Clinical Trial 21112

Phase 2 Study of Axitinib + Ipilimumab in Advanced Melanoma
Disease Site: Melanoma, skin
PI: Eroglu, Zeynep

Clinical Trial 22102

A Phase 1b, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors
Disease Site: Breast, Other Female Genital, Ovary
PI: Han, Heather

Clinical Trial 20641

A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma
Disease Site: Melanoma, skin
PI: Eroglu, Zeynep

Clinical Trial 22540

A Phase 1, open-label, multicenter, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-130037, a Kelch-like ECH-associated protein 1 (KEAP1) activator, in participants with advanced solid tumors
Disease Site: Lung
PI: Chiappori, Alberto

Clinical Trial 23652

A Phase 1, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory (R/R) CD19+ hematologic malignancies
Disease Site: Hodgkin's Lymphoma, Lymphoid Leukemia, Non-Hodgkin's Lymphoma
PI: Shah, Bijal